|
|
|
|
|
Potential of atelocollagen-mediated drug delivery system
First release of other data from an antibody drug with atelocollagen*
－Evaluation of the sustained release of peptides and proteins－
*First published as an advertisement for research reagents by KOKEN Co., Ltd.
|
|
|
In recent years, research on extracellular vesicles, including exosomes, has become more pronounced, with more than 5,000 articles published annually. Furthermore, as of June 2024, information can be found on nearly 400 clinical trials related to exosomes by searching ClinicalTrials.gov using the keyword “exosomes.”
At the recent Japanese Society for Regenerative Medicine congress, we received inquiries from individuals interested in our atelocollagen products for products suitable for regenerative medicine-related studies using exosomes and stem cell culture supernatants. Therefore, in this newsletter, we present in vitro and in vivo data on the sustained release of peptides and proteins from the atelocollagen gel.
|
|
Overview of the in vitro evaluation of atelocollagen for its sustained-release properties
|
|
|
|
Atelocollagen forms a gel under physiological conditions and has been used in a sustained-release in vivo transfection kit, “AteloGene®” which gels at the administration site. Therefore, an in vitro evaluation was performed to predict the in vivo sustained release of the active substances, excluding nucleic acids from atelocollagen.
|
|
|
|
In vitro evaluation of the sustained release of peptides and proteins
|
|
|
|
Peptides with a lower isoelectric point (pI) bonded more strongly to atelocollagen through electrostatic interactions, which resulted in a higher retention effect (each pI was measured before fluorescent labeling). In addition, it was confirmed that the larger the molecular weight (Mw) of the protein, the higher the sustained-release effect from the gel (based on in-house data).
|
|
|
|
Difference in sustained-release properties by atelocollagen concentration and the collagen-binding domain
|
|
|
|
Myoglobin (Mw 17,600, pI 6.8) showed a sustained release effect that was dependent on the atelocollagen concentration. Moreover, fibronectin with a collagen-binding domain was retained in the gel for a longer period (based on in-house data).
|
|
|
|
In vivo evaluation of antibody drugs for accelerated antitumor effects
|
|
|
|
A xenograft model of the colorectal cancer cell line HCT-116 (3 × 106 cells) was transplanted subcutaneously in the back of nude mice. Thereafter, 20 μg of bevacizumab or 20 μg of bevacizumab plus 1.0% atelocollagen was administered on Days 4 and 11 post-transplantation. The results revealed that the tumor size was significantly smaller in the bevacizumab + 1.0% atelocollagen group than in the bevacizumab alone group, indicating that atelocollagen significantly improved the drug efficacy (based on in-house data).
|
|
|
|
Atelocollagen powder for preparing high-concentration solutions
|
|
|
|
Atelocollagen powder (500 mg/bottle)
|
|
As atelocollagen solutions for research use are available in concentrations up to 0.5%, please use the powder form of this product to prepare atelocollagen solutions with concentrations greater than 0.5%.
|
|
|
|
|
|
For other pre-prepared high-concentration solutions, please contact us by clicking the button below.
|
|
|
|
|
|
